Cargando…

Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?

Epidemiological studies suggest an increased prevalence of cardiovascular disease (CVD) in patients with psoriasis (PS). Therefore, emphasis has lately been laid on the necessity for clinical evaluation of the risk of CVD in these patients. The systemic inflammatory markers C-reactive protein (CRP)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaur, Sirje, Kingo, Külli, Zilmer, Mihkel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602647/
https://www.ncbi.nlm.nih.gov/pubmed/28947858
http://dx.doi.org/10.1155/2017/7279818
_version_ 1783264597296283648
author Kaur, Sirje
Kingo, Külli
Zilmer, Mihkel
author_facet Kaur, Sirje
Kingo, Külli
Zilmer, Mihkel
author_sort Kaur, Sirje
collection PubMed
description Epidemiological studies suggest an increased prevalence of cardiovascular disease (CVD) in patients with psoriasis (PS). Therefore, emphasis has lately been laid on the necessity for clinical evaluation of the risk of CVD in these patients. The systemic inflammatory markers C-reactive protein (CRP) and interleukin- (IL-) 6, which have long been used to predict future CVD in the general population, are increased manyfold in patients with PS. Lipid abnormalities characterized by elevated triglycerides, low HDL cholesterol, and higher concentrations of LDL cholesterol and its oxidized form are also prevalent in patients. There is a need for additional laboratory markers for the assessment of cardiovascular status of patients with PS. Due to frequent comorbid overweight and obesity, biologically active compounds produced by adipocytes may have an impact on monitoring the status of the cardiovascular system of patients with PS. For this purpose, two adipokines, adiponectin and leptin, have been most extensively studied. The review focuses on some inflammatory and oxidative stress aspects in patients with PS through the analysis of the impact of prominent adipokines and oxidized low-density lipoprotein (oxLDL) to assess their eligibility for clinical practice as markers of CVD risk in patients with PS.
format Online
Article
Text
id pubmed-5602647
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56026472017-09-25 Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact? Kaur, Sirje Kingo, Külli Zilmer, Mihkel Mediators Inflamm Review Article Epidemiological studies suggest an increased prevalence of cardiovascular disease (CVD) in patients with psoriasis (PS). Therefore, emphasis has lately been laid on the necessity for clinical evaluation of the risk of CVD in these patients. The systemic inflammatory markers C-reactive protein (CRP) and interleukin- (IL-) 6, which have long been used to predict future CVD in the general population, are increased manyfold in patients with PS. Lipid abnormalities characterized by elevated triglycerides, low HDL cholesterol, and higher concentrations of LDL cholesterol and its oxidized form are also prevalent in patients. There is a need for additional laboratory markers for the assessment of cardiovascular status of patients with PS. Due to frequent comorbid overweight and obesity, biologically active compounds produced by adipocytes may have an impact on monitoring the status of the cardiovascular system of patients with PS. For this purpose, two adipokines, adiponectin and leptin, have been most extensively studied. The review focuses on some inflammatory and oxidative stress aspects in patients with PS through the analysis of the impact of prominent adipokines and oxidized low-density lipoprotein (oxLDL) to assess their eligibility for clinical practice as markers of CVD risk in patients with PS. Hindawi 2017 2017-08-29 /pmc/articles/PMC5602647/ /pubmed/28947858 http://dx.doi.org/10.1155/2017/7279818 Text en Copyright © 2017 Sirje Kaur et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kaur, Sirje
Kingo, Külli
Zilmer, Mihkel
Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title_full Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title_fullStr Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title_full_unstemmed Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title_short Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
title_sort psoriasis and cardiovascular risk—do promising new biomarkers have clinical impact?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5602647/
https://www.ncbi.nlm.nih.gov/pubmed/28947858
http://dx.doi.org/10.1155/2017/7279818
work_keys_str_mv AT kaursirje psoriasisandcardiovascularriskdopromisingnewbiomarkershaveclinicalimpact
AT kingokulli psoriasisandcardiovascularriskdopromisingnewbiomarkershaveclinicalimpact
AT zilmermihkel psoriasisandcardiovascularriskdopromisingnewbiomarkershaveclinicalimpact